ARMATA PHARMACEUTICALS, INC. Stock Issued During Period, Value, Employee Stock Purchase Plan
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- ARMATA PHARMACEUTICALS, INC. stock issued during period, value, employee stock purchase plan for fiscal 2018 was $5.00K, a 66.67% increase from fiscal 2017.
- ARMATA PHARMACEUTICALS, INC. stock issued during period, value, employee stock purchase plan for fiscal 2017 was $3.00K, a 76.92% decline from fiscal 2016.
- ARMATA PHARMACEUTICALS, INC. stock issued during period, value, employee stock purchase plan for fiscal 2016 was $13.00K.
| Period end | Stock Issued During Period, Value, Employee Stock Purchase Plan 3 month | Stock Issued During Period, Value, Employee Stock Purchase Plan 12 month |
|---|---|---|
| 2018-12-31 | $5.00K 10-K · filed 2019-03-25 | |
| 2017-12-31 | $3.00K 10-K · filed 2019-03-25 | |
| 2016-12-31 | $13.00K 10-K · filed 2018-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |